• Neurocrine Commits $175M to Voyager in New Neuro Gene Therapy Alliance

    16 days ago - By MedCity News

    Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $1.5 billion in milestone payments.
    Read more ...